ANDA 78713, held by Hikma Pharmaceuticals. Indomethacin Sodium.
As of Nov 21, 2026, ANDA 78713 (Indomethacin Sodium), held by Hikma Pharmaceuticals, was first approved by FDA on Jul 16, 2008, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 16, 2008 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Indomethacin SodiumEQ 1MG BASE/VIAL · injectable;injection | Indomethacin Sodium | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters